evidoria

← Back to browse

Good practice Imported

Medicon Valley Alliance — Cross-Border Øresund Life Science Cluster

Denmark · Copenhagen–Malmö (Øresund region) · See the Denmark profile

Evidence: Observational / pre–post Top 65% 62/100 · Ask Evidence Copilot about this practice

Active since 1997, Medicon Valley Alliance is the cross-border cluster for the Øresund life-science region (Eastern Denmark, Southern Sweden) — 400+ companies, 17 universities, 32 hospitals, ~41,000 biotech jobs, and 330+ members including Novo Nordisk and Lund University.

400+
Life-science companies in the Medicon Valley region
~41,000 jobs
Biotechnology sector employment
~100
New biotechnology and medical-technology companies founded (1998-2008)
60%
Share of Scandinavian pharmaceutical companies located in Medicon Valley (by 2008)
20%+
Life-science share of combined Denmark-Sweden GDP
330+
MVA member organisations
Medicon Valley Alliance — Cross-Border Øresund Life Science Cluster

Details

Maturity
Established
Promoter
Medicon Valley Alliance (MVA)
Period
1997–present
Keywords
life sciences, biotechnology, pharma, medtech, cross-border research collaboration

Context

Medicon Valley Alliance (MVA) is the official cross-border cluster organisation for Medicon Valley, the bi-national life-science region spanning Eastern Denmark and Southern Sweden either side of the Oresund Strait; informal collaboration began around 1992 alongside the Oresund Bridge project, and MVA has operated under its current name since 1997.

Objectives

MVA exists to coordinate universities, hospitals, companies and public bodies across the Danish-Swedish border into a shared life-science ecosystem.

Activities

MVA has grown to more than 330 members - universities, hospitals, biotech, medtech and pharma companies, contract research organisations, science parks and public bodies - and since 2011 has organised joint research around four thematic 'Beacons' (systems biology, structural biology, immune regulation and drug delivery).

Results

The region MVA coordinates is home to more than 400 life-science companies, 17 universities and 32 hospitals, employs an estimated 41,000 people in biotechnology, saw around 100 new biotech and medtech companies founded between 1998 and 2008, hosted 60% of Scandinavian pharmaceutical companies by 2008, and its life-science sector accounts for more than 20% of Denmark and Sweden's combined GDP - figures that describe the wider ecosystem rather than an audited measure of MVA's own contribution.

Conclusions

MVA is one of Europe's longest continuously operating cross-border cluster organisations, anchored by major members such as Novo Nordisk, Lundbeck and Lund University, though no documented case of another region replicating its specific governance structure was found.

Implementation
Indicative cost
Medium (€50k–€500k)
Time to results
Long (> 3 years)
Staffing & skills
Membership-based cluster organisation (330+ member institutions) rather than a single delivery team with disclosed headcount

Conditions for success

  • Sustained cross-border political and institutional commitment (informal discussions began ~1992, formalised as MVA in 1997)
  • Anchor institutions providing critical mass (Novo Nordisk, Lundbeck, Lund University)
  • Shared physical/transport infrastructure enabling the cross-border region (Oresund Bridge)
  • Long time horizon for trust-building across a national border

Common failure modes

  • Regional statistics are not separable from MVA's own causal contribution, risking overstated impact claims
  • Depends on continued cross-border regulatory and political alignment between Denmark and Sweden

Where it fits

Governance type
cross-border membership-based cluster organisation
Scale
bi-national metropolitan region

Commonly funded by

Interreg (European Territorial Cooperation) National / regional programmes

Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.

Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.

Data sources

Where this practice's information was retrieved from, and when.

Attachments

Similar practices you may find useful